Reverse Merger Brings Together Anesiva And Arcion With Focus On Pain Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Cash-strapped Anesiva finds way to continue Adlea program, targeting capsaicin formulation directly at pain sites.
You may also be interested in...
Start-Up Quarterly Statistics, Q3 2009
Highlights from the Q3 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $520 million, a 40% decrease from the previous quarter and a 45% drop from Q3 2008. Of the total money raised in the current quarter, 64% or $333 million went to the biopharma companies. Compared with Q2 2009, device fundraising decreased by 76% (from $465 million to $113 million) but diagnostics companies raised significantly more--going from $23 million to $74 million. In contrast to the previous quarter, which saw only one acquisition, in Q3 2009 there were four involving start-ups, all of which are focusing on neurological disorders. On the alliance front, three companies--Oscient, NovaMed, and Ikaria Holdings--signed two deals each this quarter.
Deals Of The Week: Anesiva/Arcion, GSK/Vernalis, Transcept/Purdue ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: Anesiva/Arcion, GSK/Vernalis, Transcept/Purdue ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.